about
Pharmacotherapies for obesity: past, current, and future therapiesLow energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort studySibutramine effects on central mechanisms regulating energy homeostasisEnvironmental exposure, obesity, and Parkinson's disease: lessons from fat and old worms.Bariatric endocrinology: principles of medical practice.Deprivation, clubs and drugs: results of a UK regional population-based cross-sectional study of weight management strategies.To evaluate efficacy and safety of Caralluma fimbriata in overweight and obese patients: A randomized, single blinded, placebo control trial.Maintenance of weight loss in adolescents: current status and future directionsThe effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United KingdomAdvances in the treatment of nonalcoholic fatty liver disease.Developing therapies for the metabolic syndrome: challenges, opportunities, and… the unknown.Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity.Sibutramine on cardiovascular outcome.The relationship between BMI and the prescription of anti-obesity medication according to social factors: a population cross sectional study.Willingness to pay for obesity pharmacotherapy.New pharmacological treatments for the management of obesity.The exaptation of endocrine pharmacology.Therapeutic Advances in Endocrinology and Metabolism: new crossroads in innovation, research, and clinical practice.A case of dilated cardiomyopathy with massive left ventricular thrombus after use of a sibutramine-containing slimming product.Weight reduction and maintenance with IQP-PV-101: a 12-week randomized controlled study with a 24-week open label period.Illicit Internet availability of drugs subject to recall and patient safety consequences.Obesity Drug Update: The Lost Decade?
P2860
Q21296814-09A0326D-552A-4019-9450-520B51C7E61FQ28750454-392F953D-844D-4786-A792-3267376072E1Q30420884-9D4EC3B2-0E41-4D33-AE8A-EB4407995EF0Q33349701-A5D1A849-1FF1-4DB6-BDCB-EEF6C385C3F3Q33677790-CB5F0ADC-7434-4FDF-B2F4-82525B362676Q33713579-581A6738-20BC-464A-AD24-105CFCDFF8BEQ34461571-27F8EAE7-A00E-42F1-8CB5-F42686284505Q34497049-DFD2C253-BD57-40B9-B6C9-6D990F3DB8F1Q36001036-BEE7B699-5F12-4E9C-B53B-A937082343B7Q36329908-F063BEAC-FBCD-4EF5-83AD-559CB08FFD76Q36329929-E01252E5-F2F7-4D45-818A-89313B01545DQ36766224-A6B972A9-27FD-49AE-89C7-D74FFA141509Q36783695-CA14BEDE-5430-4C76-AF36-25F426425D99Q37557849-79EE5AD0-32A8-41FC-899A-B869DD68E91EQ37981055-CDF39CDF-A9B9-4E98-A261-2A777006BDFCQ38211754-6A756094-7EE7-4EC9-AF5C-AE74C6CB0927Q41871093-B42CEE0B-7E3A-48B9-9150-B8657D014A8DQ42416727-622BF6D0-6BC8-4E59-B635-9554665783FDQ42933773-00751F64-E95D-41CE-BED8-5BD11A35E246Q46124082-ACF604DC-84B6-42C1-8E46-253F13B62649Q46556031-80396A3B-3086-4CF6-B34C-88A0190AE313Q46972562-62E72439-7209-41E6-934E-85DEDFE27C2F
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Withdrawal of sibutramine in Europe.
@en
Withdrawal of sibutramine in Europe.
@nl
type
label
Withdrawal of sibutramine in Europe.
@en
Withdrawal of sibutramine in Europe.
@nl
prefLabel
Withdrawal of sibutramine in Europe.
@en
Withdrawal of sibutramine in Europe.
@nl
P356
P1433
P1476
Withdrawal of sibutramine in Europe.
@en
P2093
Gareth Williams
P356
10.1136/BMJ.C824
P407
P577
2010-02-09T00:00:00Z